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infected with SIVmac32H(JS): 
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antigenic stimulation 
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Care1 A. van Baalen”, Geert van Amerongeng and Albert D.M.E. 
Osterhaus*§ 
Detailed analyses of simian immunodeficiency virus (SN)-specific cytotoxic T lympho- 
cyte (CTL) responses in vaccinated and infected macaques may help to clarzfi the role 
of CTL immunity in protection against lentiviruses. Here, the optimal conditions for 
the measurement of SIV Gag-specific CTL were investigated by bulk and limiting 
dilution assays of peripheral blood mononuclear cells (PBMC) from naive and vacci- 
nated cynomolgus macaques (Macaca fascicularis) infected with SIVmac32H(JS). In 
vitro restimulation tias generally required for CTL detection. Selective activation of 
CD8’ and MHC-restricted SIV Gag-specific CTL was induced by stimulation with 
autologous para-formaldehyde-Jixed B-lymphoblastoid cell lines infected with a recom- 
binant vaccinia virus expressing SIV Gag. Applied to limiting dilution assays, antigenic 
stimulation reproducibly demonstrated SIV Gag-specific CTL precursors (CTLp) in 
PBMC of all animals studied, including those lacking significant responses in standard 
bulk CTL assays. 0 1997 Elsevier Science Ltd. 
Keywords: animal models, protective immunity, recombinant antigens 
Even though cytotoxic T lymphocytes (CTL) are 
believed to contribute to the control of human and 
animal viral infections, their role in the host defense 
against lentiviruses has not been firmly established’. 
Infection of macaques with several strains or clones of 
simian immunodeficiency virus (SIV)mac shows 
remarkable similarities with human immunodeficiency 
virus (HIV) infection of humans2. Following SIV 
inoculation, a burst of virus replication is observed, 
which rapidly subsides in coincidence with the develop- 
ment of antiviral immune responses3. The subsequent 
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course of the infection varies considerably among 
macaques: some animals rapidly develop an AIDS-like 
disease and die within few weeks or months, whereas 
others may remain asymptomatic for > 3 years. This 
individual variability, combined with the opportunity to 
define parameters of infection such as strain, dose and 
route of virus inoculation, may prove valuable for clari- 
fying the role of CTL immunity in the control of lenti- 
viral infections. 
We4 and others5,6 have reported recently that 
vaccine-induced SIV Env-, Gag-, or Nef-specific CTL 
failed to protect macaques upon challenge with cell- 
free SIVmac. In the same model, however, Gallimore 
et al.’ found an inverse correlation between the 
frequency of vaccine-induced SIV Nef-specific CTL 
precursors (CTLp) and peak virus load measured after 
challenge. These findings indicate that CTL may not be 
able to prevent or control HIV or SIV infection, unless 
stringent qualitative and quantitative requirements are 
met. Detailed analyses of CTL responses in both vacci- 
nated and infected macaques may help to clarify these 
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requirements, thereby facilitating the design of 
immunotherapeutic intervention#. However, initial 
reports have indicated that CTLp frequencies of 
immunized and naive rhesu?.’ or cynomolgus”.‘.“’ 
macaques infected with SlVmac may be relatively low 
by comparison with those often measured in HIV-I 
infected humans”, implying that sensitive and repro- 
ducible methods are required to evaluate CTL 
responses in macaques. Extending observations 
previously made in HIV-1 infected humans”,“, we 
report here that in vitro expansion of effector cells 
under limiting dilution conditions by stimulation with 
SIV Gag recombinant vaccinia virus (rVV)-infected 
and para-formaldehyde (pfa)-fixed B-lymphoblastoid 
cell lines (B-LCL), significantly enhances CTL detec- 
tion in both immunized and naive cynomolgus 
macaques infected with SlVmac32H(JS). 
MATERIALS AND METHODS 
Animals 
The study included eight colony-bred juvenile 
(1.5-3.5 years) cynomolgus macaques seronegative for 
SIV, type D simian retrovirus (SRV) and simian T cell 
leukaemia virus-l (STLV-I). Four monkeys (designated 
K77*, K80*, K83* and K88*) were immunized with an 
SIV Env-lscoms, Gag-lscoms and Nef-lipopeptides 
subunit vaccine, as described4. The other four monkeys 
(K73, K79, K66 and K71) were naive at the time of 
SIV infection. Animals were inoculated intravenously 
with 50 monkey median infectious doses of cell-free 
SlVmacJ5, a pathogenic molecular clone derived from 
SlVmac32H and grown on rhesus peripheral blood 
mononuclear cells (PBMC)“. Infection was confirmed 
by virus isolation”, antibody detection in ELlSA and 
nested-Gag PCRIS. 
PBMC preparation 
Blood samples were drawn from the femoral vein 
into tubes containing heparin. PBMC were separated 
by density gradient centrifugationJ, washed three times 
in complete RPM1 1640 medium (containing 
1OOU ml ’ penicillin, 100 pg ml-’ streptomycin. 
lo-” M P-mercapto ethanol and 2 mM L-glutamine), 
and either used immediately or cryopreserved. Cell 
viability (as assessed by Trypan Blue exclusion) 
exceeded 95% after thawing. Cell-associated virus load 
was determined in serial dilutions of freshly isolated 
PBMC co-cultured with the human T cell line C8166; 
the lowest dilution contained 10h PBMC4. Herpes 
papio-transformed B-LCL were established by incuba- 
tion of PBMC with cell-free supernatant from the 
Herpes papio-producing cell line S594, and maintained 
in complete medium containing 10% foetal calf serum 
(FCS; R-10). Serological MHC typing was performed 
by Dr R. Bontrop (BPRC, Rijswijk, The Netherlands). 
SIV p26 core antigen in plasma was assayed by 
antigen-capture ELISA (Coulter SIV Core Antigen 
Assay, Coulter Electronics, Mijdrecht, The 
Netherlands). 
Immunomagnetic cell fractionation 
PBMC in complete medium with 2% FCS were 
mixed with magnetic beads coated with anti-CD8 
monoclonal antibodies (mAb) (Dynabeads M-450. 
Dynal, Oslo, Norway) at a 1:lO target cell-to-bead 
ratio’“. After incubation for 60 min at 4°C fractions 
were separated on a magnetic separation device 
(MPC-6, Dynal). Positively selected CD8+ cells were 
detached from magnetic beads using a goat anti- 
mouse-Fab polyclonal antiserum (DETACHaBEAD, 
Dynal). This separation procedure yields highly pure 
cell populations, without interfering with either CD8 
expression or cytotoxic function of effector cellslh. By 
immunofluorescence analysis positively selected 
fractions typically consisted of > 99% CD8’ cells, 
whereas CD8+ contamination of depleted fractions was 
consistently ~2% (data not shown). 
Immuuofluorescence analysis 
Cell samples in PBS with 0.1% BSA were incubated 
for 30 min at room temperature with anti-CD2 
(Leu-Sb-fluorescein isothiocyanate, Becton Dickinson, 
Mountan View, CA) and anti-CD8 (Leu-2a-phycoery- 
thrin, Becton Dickinson) or anti-CD4 (OKT4-FITC, 
Ortho Diagnostic System, Raritan, NJ) mAb. Samples 
were washed twice with PBS, fixed in 1.5% pfa and 
analysed with a FACScan (Becton Dickinson). 
Preparation of antigen presenting cells (APC) 
Autologous B-LCL were infected overnight with 
rVV (10 m.o.i.) expressing either the Gag ~56 gene of 
SlVmac32H (kindly provided by Professor A. 
McMichel, Institute of Molecular Medicine, Oxford, 
UK) or the Tat gene of SlVmac251 (TG4174, kindly 
provided by Dr M.P. Kieny, Transgene, Strasbourg, 
France), and subsequently fixed in 1.5% pfa, as 
described”. Autologous irradiated (8500 rad) SIV Gag 
rVV-infected B-LCL were used as APC in a limited 
number of experiments. Cultures stimulated with these 
APC showed no signs of vaccinia virus-induced 
cytopathic effects. Antigen expression in SIV Gag APC 
was confirmed by immunofluorescence analysis using a 
polyclonal bovine anti-vaccinia serum (RIVM, Bilt- 
hoven, The Netherlands) and the murine anti-Gag 
mAb CLB14 (CLB, Amsterdam, The Netherlands). 
Bulk culture conditions 
Bulk assays were done with either unstimulated or 
restimulated PBMC. For antigenic stimulation, PBMC 
(2.5 x lo4 per well) in R-10 were cultured for 14 days in 
96-well round-bottomed plates with SIV Gag or Tat 
APC (lo4 per well) and autologous irradiated 
(2500 rad) feeder PBMC (lo4 per well). Cultures were 
supplemented with 10 U ml-’ recombinant interleukin 
(IL)-2 (rlL-2) from day 3, and restimulated with lo4 
per well APC on day 7. During the second cycle of 
stimulation the culture medium was enriched with 10% 
supernatant from concanavalin A (ConA)-stimulated 
blasts. In some experiments, PBMC (10’ ml-‘) were 
cultured for lo-14 days with autologous irradiated 
PHA-blasts infected with SlVmac32H(JS) (lo5 ml-‘), 
as described by Gotch et af.“. For mitogenic stimula- 
tion, PBMC ( lo6 ml-‘) were cultured for 3 days with 
ConA (5 pg ml-‘), washed, and expanded with rlL-2 
(20 U ml-‘) for 4- 11 days. Effector cells were assayed 
for cytotoxicity in duplicate or triplicate wells at 
indicated effector-to-target cell (E:T) ratios. 
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Limiting dilution culture conditions 
Limiting dilution assays were done with either unsti- 
mulated or restimulated PBMC, to estimate CTLIX and 
CTLp frequencies respectively. PBMC restimulation 
was performed as described for bulk assays. The 
optimal limiting dilution assay parameters, including 
numbers and ranges of dilutions, and numbers of repli- 
cate wells, were predetermined for each monkey in a 
pilot experiment. All assays included at least four and 
up to eight PBMC dilutions, and each dilution included 
at least 24 and up to 48 replicate wells of 96-well 
round-bottomed plates. Three or four aliquots from 
each well were tested in split-well cytotoxicity assays. 
Cytotoxicity assay 
Cytotoxicity was measured in standard “Cr-release 
assays against autologous and allogenic MHC class I 
mismatched B-LCL infected overnight with 10 m.o.i. of 
SW Gag or Tat rVV. Autologous B-LCL either 
infected with 186-poly rVV (containing a polycloning 
site without insert and kindly provided by Dr M.P. 
Kieny, Transgene) or incubated with medium alone 
served as control. Targets were labelled for 1 h with 
100 &i of “‘0, washed three times, resuspended in 
R-10, and added to effector cells at 5 x 10. cells per 
well in 96-well round-bottomed plates (Costar, 
Cambridge, UK). After a 5 h incubation, supernatants 
were harvested (Skatron Harvester, Skatron, Oslo, 
Norway), and the release of 5’Cr was measured in a 
gamma counter. Maximum 5’Cr release was determined 
by detergent (5% Triton X-100) lysis of target cells. 
Spontaneous release was determined by incubation of 
target cells in R-10 alone. Spontaneous release was 
<30% of maximum release. 
Calculation of results 
The percentage of lysis of specific and control targets 
was calculated for duplicate or triplicate wells of bulk 
cultures and for each well of limiting dilution cultures 
according to the formula: %lysis = [(experimental 
release -spontaneous release)/(maximum release 
-spontaneous release)] x 100. Individual wells of 
limiting dilution cultures were considered positive 
when lysis of specific targets exceeded by 10% that of 
control targets if the latter was <lo%, or by 20% if 
the latter was > 10%. In all positive wells the experi- 
mental release exceeded the spontaneous release by at 
least three standard deviations (S.D.). CTLp frequen- 
cies were estimated by the maximum likelihood 
method using the statistical software packa e described 
by Strijbosch et al.“‘, 9 which included a x goodness- 
of-fit test statistic. Frequencies were normalized to the 
number of CTLp per 10h PBMC. Rates of change/ 
month of follow-up (slopes), and correlation coeffi- 
cients (r) of virus load, CTLp frequencies and CD4+ 
cell percentages were calculated by linear regression 
analysis. 
RESULTS 
Measurement of SIV Gag-specific CTL in bulk assays 
SW Gag-specific CTL responses were studied in 
eight cynomolgus macaques during the first 4 months 
of infection with SIVmac32H(JS). Four monkeys (indi- 
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cated by an asterisk) had been immunized before infec- 
tion with an SIV Env-Iscoms, Gag-Iscoms and 
Nef-lipopetides subunit vaccine4, whereas the other 
four animals were naive at time of virus inoculation. 
To establish optimal conditions for CTL measurement, 
we first compared in bulk assays the direct SIV 
Gag-specific CTL responses of unstimulated PBMC 
with those mediated by the same PBMC following 
either mitogenic or antigenic in vitro restimulation. As 
shown in the examples of Figure lA, no significant CTL 
responses against SIV Gag were mediated by unstimu- 
lated PBMC in E:T ratios up to 2OO:l. After mitogenic 
expansion with ConA (Figure ZB), effector cells 
specifically reactive against SW Gag were detected in 
monkey K71, whereas relatively high levels of 
non-specific background lysis hindered reliable CTL 
measurement in monkey K88*. In parallel, the specific 
lysis of SIV Gag rVV-infected targets was markedly 
enhanced by two l-week cycles of antigenic stimula- 
tion, using as APC autologous pfa-fixed B-LCL 
infected with SIV Gag rVV (Figure IC). 
Previously we’” and others”’ have shown that after 
pfa-fixation, Epstein-Barr virus-transformed B-LCL 
retain their ability to induce CTL activation, but lose 
their release of helper-like soluble factors. These 
factors are known to stimulate the growth of both 
MHC restricted and unrestricted cytotoxic cells reac- 
tive against the B-LCL’“.“‘. Extending these observa- 
tions to Herpes papio-transformed B-LCL, we 
observed that stimulation of PBMC from monkey K88* 
with pfa-fixed SIV Gag APC elicited SIV Gag-specific 
-0-w control 
-V- medium control 
50 100 200 
E:T 
ic 
/ 
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Figure 1 In vitro restimulation is required to detect SIV 
Gag-specific CTL in PBMC of immunized and non-immunized 
cynomolgus macaques infected with SIVmac32H(J5). Data are 
shown for two monkeys. Monkey K88* had been immunized with 
an SIV Env-lscoms, Gag-lscoms and Nef-lipopeptides subunit 
vaccine before infection. Monkey K71 was naive at the time of 
virus inoculation. Effector cells were: (A) unstimulated PBMC 
isolated either 12 weeks (monkey K71) or four months (monkey 
K88*) after infection; (B) the same PBMC expanded by mitogenic 
stimulation with ConA, and assayed twice, either on days 10 (. .) 
and 14 (-) of culture (monkey K71), or on days 7 (. .) and 10 
(-) of culture (monkey K88*); (C) the same PBMC expanded by 
two l-week cycles of antigenic stimulation, using as APC 
autologous pfa-fixed B-LCL infected with SIV Gag rW. Targets 
were autologous B-LCL either infected with SIV Gag rW or with 
vaccinia virus (vv) control, or uninfected (medium control). Results 
are expressed as mean specific lysis *SD from triplicate (A and 
B) or duplicate (C) well estimations 
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Figure 2 Stimulation efficiency of SIV Gag APC. Effector cells 
were generated by stimulation of PBMC from monkey K88* with 
either pfa-fixed (A) or irradiated (B and C) SIV Gag APC. Targets 
were autologous B-LCL either infected with SIV Gag rW or with 
vaccinia virus (w) control, or uninfected (medium control). For 
cold target inhibition (C), non-labelled uninfected B-LCL were 
mixed with the “Cr-labelled targets at a ratio of 51 before the CTL 
assay was initiated. Results are expressed as mean specific lysis 
with SD. from duplicate well estimations at an E:T ratio of 4O:l 
CTL without significant expansion of cytotoxic cells 
reactive against control targets (Figure 2A). In contrast, 
after stimulation of the same PBMC with irradiated 
SIV Gag APC (Figure 2B and C), relatively high 
numbers of cold (non-5’Cr-labelled) uninfected targets 
were required to inhibit non-specific background lysis 
and measure SIV Gag-specific CTL. 
In monkey K71, effector cells generated by stimula- 
tion with either SIV Gag (Figure 3A) or Tat (Figure 
3B) APC mediated significant lysis of targets infected 
with the inducing rVV, but not of targets infected with 
either the discordant rVV or with vaccinia virus 
control. This finding confirmed that antigenic stimula- 
tion induces selective CTL activation. Furthermore, 
immunofluorescence analyses indicated an expansion 
of CD8’ cells at the end of the two cycles of SIV 
Gag-specific stimulation (data not shown). Depletion 
studies confirmed that SIV Gag-specific CTL were 
indeed CD8’ cells: as shown in Figure 4 for monkey 
K71, SIV Gag-specific CTL responses mediated by 
total effector cells were preserved in positively isolated 
CD8’ cells, but were abolished by CD8-depletion. In 
addition, these responses were restricted to autologous 
targets, whereas allogenic MHC class-I mismatched 
targets infected with SIV Gag rVV were not 
recognized. 
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Figure 3 Selective expansion of antigen-specific CTL. Effector 
cells were generated by stimulation of PBMC from monkey K71 
with either SIV Gag (A) or Tat (B) APC. Targets were autologous 
B-LCL infected with either SIV Gag or Tat rW or with vaccinia virus 
(w) control. Results are expressed as mean specific lysis with S.D. 
from duplicate well estimations 
I 
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Figure 4 CD8+ cell-mediated and MHC-restricted cytotoxic 
responses against SIV Gag. Effector cells generated by stimulation 
of PBMC from monkey K71 with SIV Gag APC were assayed as 
total cell population, positively isolated CD8’ cells (>99% CDB’), 
and CD8-depleted cell population (<2% CD8’). Targets were 
autologous B-LCL infected with either SIV Gag rW or with vaccinia 
virus (w) control, and allogenic SIV Gag rW-infected B-LCL from 
three MHC class-l mismatched monkeys 
Measurement of SW Gag-specific CTL and CTLp in 
limiting dilution assays 
The frequencies of SIV Gag-specific CTL and CTLp 
were estimated by limiting dilution assays of unstimu- 
lated and restimulated PBMC, respectively. The 
optimal assay parameters (i.e. numbers and ranges of 
dilutions and numbers of replicate wells) yielding x” 
goodness-of-fit test statistic < 10 were predetermined 
in a pilot experiment for each monkeys. Single-well 
cytotoxic responses of restimulated PBMC from 
monkey K71 are shown in Figure 5. In agreement with 
the results of bulk CTL assays (Figure IC), after two 
l-week cycles of SIV Gag-specific stimulation, effector 
cells in most wells mediated killing of SIV Gag 
rVV-infected targets (Figure 5A), with negligible killing 
of control targets (Figure 5B). The relationship 
between the percentage of negative wells and the initial 
cell number was consistent with the single-hit Poisson 
model and indicated a CTLp frequency of 58 (95% 
confidence interval: 44-72; x1:1) per 10” PBMC (Figure 
X, filled circles). In contrast, in the absence of PBMC 
restimulation, SIV Gag-specific CTL were detected at 
a frequency of only two (0.3-3; x2:1) per 10” PBMC 
(Figure 5C, filled triangles). Similarly, 4 months after 
infection, the frequency of SIV Gag-specific CTL in 
unstimulated PBMC of monkey K88* was only 2 
(0.4-4; x2:4) per 10” PBMC, whereas no CTL could be 
detected in unstimulated PBMC of other monkeys 
(data not shown). These findings confirmed that in vitro 
restimulation greatly amplifies SIV Gag-specific CTL 
responses. 
Cell culture under limiting dilution conditions 
further increased the sensitivity of CTL measurement. 
Even after SIV Gag-specific PBMC restimulation, 
monkeys with low, but still measurable CTLp frequen- 
cies (< 10 per 10” PBMC), showed no consistent CTL 
responses in standard bulk CTL assays, using E:T 
ratios up to 1OO:l. As an example, a comparison of 
bulk and limiting dilution assays of PBMC from 
monkey K66 is shown in Figure 6. In bulk assays (Figure 
6A), no significant lysis of SIV Gag rVV-infected 
targets was mediated by PBMC that were unstimulated 
or restimulated with either ConA or SIV-infected 
blasts. Lysis increased after SIV Gag-specific stimula- 
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Figure 5 Limiting dilution analysis of cytotoxic responses against SIV Gag. PBMC isolated from monkey K71 at week 12 after infection 
were cultured in six dilutions (range: 40000 to 3815 cells per well), each including 24 replicate wells. After two l-week cycles of SIV 
Gag-specific stimulation, individual wells were tested against (A) autologous B-LCL infected with SIV Gag rW, and (B) autologous B-LCL 
either infected with vaccinia virus (w) control or uninfected (medium control), and allogenic SIV Gag rW-infected B-LCL from one MHC 
class-l mismatched monkey. (C) Frequency analysis of SIV Gag-specific CTL and CTLp in unstimulated and restimulated PBMC, respec- 
tively. The relationship between the percentage of negative wells and the initial cell number was consistent with the single-hit Poisson 
model. Frequencies were estimated by the maximum likelihood method and normalized to number of CTL or CTLp per lo6 PBMC. Dotted 
lines indicate 95% confidence intervals. The frequency of SIV Gag-specific CTL was 2 (0.3-3; x2: 1) per 10” PBMC. The frequency of SW 
Gag-specific CTLp was 58 (44-72; x2: 1) per 1 O6 PBMC 
tion, but it was still ~10% after subtraction of 
non-specific background lysis. In limiting dilution 
assays, SIV Gag-specific CTLp were detected at a 
frequency of four (2-6; x”: 1) per 10” PBMC (Figure 
6B). 
The reproducibility of CTLp frequency estimates 
was verified in 10 replicate assays of cryopreserved 
PBMC, which showed a mean coefficient of variation 
(as 100 x the S.D. of the residuals/mean CTLp 
frequency estimate) of 9.5% (data not shown). We also 
investigated the ability of SIV Gag APC to stimulate 
unprimed CTLp in naive PBMC isolated from the 
eight monkeys before exposure to either whole SIV or 
SIV antigens. These PBMC were assayed in parallel 
with those obtained 4 months after infection, using 
identical culture and assay conditions. The individual 
wells of limiting dilution assays were never or rarely 
positive in naive PBMC (CTLp frequencies < 1 per 10” 
PBMC stimulation 
A 
SIV 
SIV Gag APC 
-infected blasts 
ConA 
1. SlV,Gag C’,‘p ‘**.., 1 
0 20 40 60 
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Figure 6 Bulk and limiting dilution assays of PBMC isolated from 
monkey K66 at week 12 after infection. In bulk assays (A), PBMC 
were unstimulated or restimulated with either ConA, or 
SIV-infected blasts, or SIV Gag APC, and assayed in duplicate at 
an E:T ratio of 8O:l. In limiting dilution assays (B), PBMC were 
restimulated with SIV Gag APC. Target cells were autologous 
B-LCL either infected with SIV Gag rW or with vaccinia virus (w) 
control (A and B) or uninfected (medium control, B). The 
frequency of SIV Gag-specific CTLp was 4 (2-6; x2:1) per lo6 
PBMC 
PBMC, data not shown), indicating that only primed 
CTLp were responsive to SIV Gag-specific stimulation. 
Kinetics of SIV Gag-specific CTLp 
In kinetic studies of the four monkeys that were 
naive at the time of virus inoculation, SIV Gag-specific 
CTLp were first detected between week 1 and 4 (K71, 
K73, K79) or 9 (K66) after infection (Table 1). CTLp 
detection in circulation coincided therefore with the 
containment of PBMC-associated virus load and p26 
antigenemia which followed the initial virus burst 
observed at week 2 or 4 after infection”. The four 
vaccinated monkeys (K77*, K80*, K83* and K88*) had 
developed SIV Gag-specific CTLp upon immunization, 
at frequencies ranging from 2 to 13 per 10” PBMC”. 
After infection, their CTLp frequencies were still 
similar to those found in the non-immunized animals 
(Table 2). In all eight monkeys, frequencies were gener- 
ally maintained between week 12 and 4 months after 
infection, but a marked increase was observed in 
monkey K88*. Overall, no clear correlation emerged 
between CTLp frequencies and PBMC-associated virus 
load. In fact, 4 months after infection statistical analysis 
seemed to suggest a strong positive correlation 
between virus load and CTLp frequencies (r = 0.89, 
P = 0.003, not shown); however, this relationship was 
lost if monkey K88* was excluded from analysis. All 
eight monkeys remained asymptomatic during the first 
4 months of infection. Six animals showed a progressive 
decline of CD4’ cell percentages, which was 
pronounced in monkeys K73 and K79 (Table I). 
DISCUSSION 
In the present study, we have studied the CTL 
responses of immunized and naive cynomolgus 
monkeys after infection with SIVmac32H(JS). We 
focused our attention on responses directed against the 
relatively conserved Gag protein, which has been 
described as a major target of CTL immunity against 
lentiviruses”.“.“. Our findings demonstrate that anti- 
genie stimulation of effector cells under limiting dilu- 
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Table 1 Evaluation of virological and immunological parameters in vaccinated and naive cynomolgus macaques infected with 
SIVmac32H(J5)a 
Monkey Virus loadb 
2-4 week (peak) 4 months 
CTLp” 
l-4 weeks’ 6- 12 weeks? 4 months 
CD4’ cell slope” 
K66 503 <l 0 4 (2-6; 1) 5 (3-7; 3) -1.7&l 
K71 > 1000 <l 27 (17-37; 4) 58 (44-72; 1) 56 (42-70; 3) +1+1.5 
K73 625 5 12 (8-17; 2) 9 (6-13; 1.5) 7 (5-9; 3) -4.3kO.5 (P<O.O5) 
K79 >lOOO 6 14 (8-20; 1) 11 (15-26; 2.5) 12 (8-15; 4) -3.2kO.8 (P<O.O5) 
K77* 208 25 3 (l-5; 3) 7 (4-9; 2) 9 (6-12; 4) -0.620.6 
K80* 208 3 8 (4-12; 2) 15 (10-21; 1) 12 (8-16; 2.5) -0.610.3 
K83* >lOOO 3 12 (9-16; 1) 13 (9-17; 1) 10 (7-14; 1) -1.3*0.9 
K88* >lOOO 156 N.D. 18 (12-24; 1) 121 (95-147; 1) -2.4*1 
“Data are presented for eight animals. Four monkeys (denoted by an asterisk) had been immunized with an SIV Env-lscoms, Gag-lscoms, 
Nef-lipopetides subunit vaccine before infection, whereas the other four animals were naive at the time of virus inoculation 
bCell-associated virus load was measured in co-cultures of PBMC with C8166 cells and normalized to the number of infected cells per lo6 
PBMC 
“Effector cells were generated under limiting dilution culture conditions by stimulation with autologous pfa-fixed B-LCL infected with SIV Gag 
rW. Split-well “Cr-release assays were performed on day 14 of culture. Frequencies were estimated by the maximum likelihood method 
and normalized to the number of CTLp per lo6 PBMC; 95% confidence intervals and x2 goodness-of-fit test statistics are given in 
parentheses 
?tesults are presented from one of at least two experiments, with coefficients of variation < 10% 
“Rates of change (slopes) in CD4+ cell percentages month-’ were determined by linear regression analyses of longitudinal data obtained 
at minimum three time points (mean = 3.75) during 4 months of observation. Positive slopes indicate increase, negative slopes correspond 
to a decrease 
tion conditions provides a sensitive and reproducible 
approach to characterize CTL responses against SIV. 
With this approach we were able to detect SIV 
Gag-specific CTLp in PBMC of all animals studied, 
including those lacking significant CTL responses in 
standard bulk CTL assays (Figure 6). 
In vitro restimulation was shown to be required to 
amplify SIV Gag-specific CTL responses to detectable 
levels (Figure 1). In contrast, Gag-specific CTL 
responses of asymptomatic HIV-1 -infected adults have 
often been of sufficient magnitude to allow detection in 
primary assays, in the absence of in vitro restimula- 
tion”.“. In line with these observations, and in agree- 
ment with previous studies of SIVmac-infected rhesus”,” 
and cynomolgus”’ macaques, SIV Gag-specific CTLp 
were detected at frequencies generally lower than 
those measured in asymptomatic HIV-l-infected 
adults’3.“. This discrepancy may reflect a relatively low 
degree of antigenic stimulation in macaques, due to 
rapid downregulation of SIV replication after infection. 
Our kinetic studies appear to support this hypothesis. 
Immediately after infection, we found that CTLp 
detection in the naive macaques coincided with the 
initial decline of cell-associated virus load and p26 anti- 
genemia. Subsequently, we found no significant differ- 
ences in the CTLp frequencies of immunized and naive 
monkeys. whereas a positive correlation seemed to 
develop between virus load and the frequencies of SIV 
Gag-specific CTLp in the monkey showing relatively 
poor virus containment (Table I). Taken together, 
these observations support the hypothesis that the 
rapid development of CTL responses targeting certain 
critical viral proteins or epitopes may indeed contribute 
towards the initial virus containmentZ’.Z’. However, as 
also suggested by Ferbas ef al?, in cases of poor virus 
control, CTLp frequencies may become a reflection of 
persistently high levels of antigenic stimulation. 
To stimulate the growth of SIV Gag-specific CTLp 
we used autologous B-LCL infected with SIV Gag rVV 
and fixed in pfa. With a similar approach, we have 
been able to demonstrate Gag-specific CTLp in PBMC 
from HIV-l-infected persons, even after the onset of 
1274 Vaccine 1997 Volume 15 Number 11 
overt disease13. In the macaques, in vitro antigenic 
stimulation was shown to promote the selective expan- 
sion of SIV Gag-specific CTL of the CD8’ MHC class- 
I restricted phenotype (Figure 3Figz.ue 4Figure 5). As a 
result, CTL detection was enhanced compared with 
results obtained after mitogenic stimulation with ConA 
(Figure I), a well-established method for CTL expan- 
sion“. Other authors have also reported the use of 
rVV to expand CTL against HIV” or SIV’” antigens. 
In the study by Lubaki et a1.‘5, the use of irradiated 
rVV-infected B-LCL as APC caused high levels of 
non-specific background lysis, and cold target inhibition 
was required to detect HIV-specific CTL. In our study, 
PBMC stimulation with irradiated SIV Gag APC also 
allowed CTL detection in bulk assays when combined 
with cold target inhibition (Figure 2). However, this 
method did not allow a reproducible measurement of 
CTLp frequencies in limiting dilution assays (data not 
shown). Along the same line, Kent et al.‘” had to 
replace irradiated rVV-infected B-LCL with irradiated 
rVV-infected PBMC as APC to reduce the growth of 
non-specific cytotoxic cells and measure SIV-specific 
CTL. The improved ratio of specific to non-specific 
lysis we obtained with pfa-fixed APC (Figure 2), prob- 
ably resulted from an adequate preservation of their 
stimulation efficiency, together with a reduced release 
of T-helper like soluble factors that may stimulate the 
growth of non-SIV-specific cytotoxic cells’3.Z”. 
Interestingly, a previous study by Venet et al.” 
described an earlier development of SIV-induced 
disease in those monkeys which lacked detectable CTL 
responses. All our monkeys remained asymptomatic 
during the first 6 months of observation. Among the six 
animals with relatively low CTLp frequencies, five 
showed a progressive decrease of CD4’ cell percent- 
ages, which was pronounced in only two cases 
(Tahlr I). Nonetheless, a longer follow-up may clarify 
whether the generation of higher SIV Gag-specific 
CTLp frequencies may be associated with a better 
long-term control of the infection in some monkeys. 
Studies are in progress to address this hypothesis, 
which may contribute to the design of effective vaccina- 
Detection of SIV Gag-specific CTL: A-M. Geretti et al. 
tion strategies for the prevention and control of lenti- 
viral infections. 
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